People living with Friedreich’s ataxia in Ireland have received a major boost after the HSE approved the reimbursement of Skyclarys, the first drug specifically approved to treat the progressive neurological condition.
The decision means patients will no longer face the enormous financial burden of accessing the medication out of pocket, a reality that had previously put the treatment out of reach for many of those who need it most.
Friedreich’s ataxia is a rare inherited condition that damages the nervous system over time, gradually affecting movement, balance and coordination. It typically appears in childhood or early adulthood and can also cause serious heart problems. There is no cure, making effective treatments like Skyclarys all the more critical for those diagnosed with the condition.
Skyclarys, known generically as omaveloxolone, was developed by Reata Pharmaceuticals and works by targeting the underlying cellular dysfunction that drives the disease. It received approval from the European Medicines Agency, and advocacy groups in Ireland had been pushing hard for the HSE to follow through with a reimbursement decision so that patients could actually access it through the health system.
For families and individuals who have been waiting on this call, the news is a genuine lifeline. Friedreich’s ataxia affects a small but significant number of people in Ireland, and those living with the condition have often described the exhausting process of fighting for access to treatments that exist but remain financially or administratively out of reach.
The reimbursement approval means the drug will now be covered under the health system, removing the cost barrier that had stood between patients and a treatment that can help slow the progression of their symptoms. For a condition that steadily robs people of their independence, even slowing that progression can make a profound difference to quality of life.
Patient groups who campaigned for this outcome have welcomed the HSE decision warmly, describing it as a long overdue recognition of the needs of people living with rare diseases in Ireland. Rare disease advocates have long argued that the reimbursement process in Ireland can be painfully slow, leaving patients in a frustrating limbo while treatments sit approved but inaccessible.
This decision adds to a broader conversation about how Ireland handles rare disease treatments and whether the current system moves quickly enough to support patients who often have very few alternatives available to them. With a small patient population and limited treatment options, delays in reimbursement decisions can have an outsized impact on individuals and their families.
For now though, the focus is on the positive. Irish patients with Friedreich’s ataxia can now access Skyclarys through the health system, marking a significant step forward in the care available to them.